EUVIMEDEUVIMED entdecken
Crossref

In Brief: Zanubrutinib (Brukinsa) for CLL or SLL

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1670e ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa), which was previously approved by the FDA for treatment of mantle cell lymphoma, Waldenström's macroglobulinemia, and relapsed or refractory marginal zone lymphoma, has now been approved for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults. The BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence) were approved earlier for treatment of CLL and SLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellHumansPiperidinesPyrazolesPyrimidines

Stichwörter der Autor:innen

BrukinsaCalquenceImbruvicaacalabrutinibadverse effectsdosagedrug interactionsefficacyibrutiniblactationleukemialymphomapregnancysafetyzanubrutinib

Substanzen

zanubrutinibPiperidinesPyrazolesPyrimidines

Zitieren

APA

(2023). In Brief: Zanubrutinib (Brukinsa) for CLL or SLL. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670e

Vancouver

In Brief: Zanubrutinib (Brukinsa) for CLL or SLL. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670e

BibTeX
@article{euvimed2023,
  title = {In Brief: Zanubrutinib (Brukinsa) for CLL or SLL},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1670e}
}
Kostenlos starten →